AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23838975 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive strength training group (TG)
Number of subjects: 36
Study 23838975 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 22727160 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone (50/100 μg twice daily)
Number of subjects: 105
Study 22727160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (100 μg twice daily)
Number of subjects: 105
Study 22727160 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 105
Study 22727160 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone
Number of subjects: 105
Study 22727160 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 105
Study 19719551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-estradiol + 10 mg dydrogesterone
Number of subjects: 72
Study 19719551 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17beta-estradiol + 10 mg dydrogesterone
Number of subjects: 72
Study 19719551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18929285 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.20%
Number of subjects: 40
Study 18929285 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.20% plus sufentanil 0.5 microg kg(‐1)
Number of subjects: 40
Study 17175700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin with omeprazole (Group A)
Number of subjects: 50
Study 17175700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 50
Study 12811706 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nasal sumatriptan
Number of subjects: 29
Study 12811706 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of intravenous ketorolac
Number of subjects: 29
Study 11179942 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral information only
Number of subjects: 115
Study 11179942 — intervention group
Group type: COMPARATOR
Intervention: Combination of oral and written information
Number of subjects: 115
Study 11179942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study 8646433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg i.v. infusion)
Number of subjects: 15
Study 8646433 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 15
Study 8646433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RA and controls) after naloxone treatment
Number of subjects: 15
Study 8646433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RA and controls) after any treatment
Number of subjects: 15
Study 8646433 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain score in RA group
Number of subjects: 15
Study 1815648 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (200 mEq/day) in salt-sensitive (SS) men
Number of subjects: 27
Study 1815648 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (200 mEq/day) in salt-resistant (SR) men
Number of subjects: 27
Study 1815648 — intervention group
Group type: COMPARATOR
Intervention: Low NaCl diet (20 mEq/day)
Number of subjects: 27
Study 6337421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin, 250 mg every six hours for 72 hours
Number of subjects: 499
Study 6337421 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 499
Study 30004561 — intervention group
Group type: EXPERIMENTAL
Intervention: TESSYS
Number of subjects: 462
Study 30004561 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical treatment with posterior approach (Control)
Number of subjects: 462
Study 27318612 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL Curriculum
Number of subjects: 8
Study 27318612 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 24834977 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept treatment
Number of subjects: 0
Study 24834977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23131066 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate therapy (2.5-second delay at heart rate ≥200 bpm)
Number of subjects: 1500
Study 23131066 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed therapy (60-second delay at 170-199 bpm, 12-second delay at 200-249 bpm, 2.5-second delay at ≥250 bpm)
Number of subjects: 1500
Study 23131066 — intervention group
Group type: COMPARATOR
Intervention: Conventional programming (2.5-second delay at 170-199 bpm, 1.0-second delay at ≥200 bpm)
Number of subjects: 1500
Study 21087922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention arms
Number of subjects: 2513
Study 21087922 — intervention group
Group type: COMPARATOR
Intervention: Untailored intervention arm
Number of subjects: 2513
Study 18490498 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin delta
Number of subjects: 60
Study 18490498 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epoetin alfa
Number of subjects: 60
Study 16283958 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of 2% lidocaine
Number of subjects: 85
Study 16283958 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of 0.5% bupivacaine
Number of subjects: 85
Study 16283958 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of 2% lidocaine and 15 mg of 0.5% bupivacaine
Number of subjects: 85
Study 12467943 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg meta-chlorophenylpiperazine (MCPP)
Number of subjects: 31
Study 12467943 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ipsapirone
Number of subjects: 31
Study 12467943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10342343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg per day for 4 months
Number of subjects: 37
Study 10342343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7857144 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy
Number of subjects: 19
Study 7857144 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 19
Study 1940815 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0
Study 1940815 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0
Study 7141761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) pretreatment (p.o. 5.0 g/24 h)
Number of subjects: 16
Study 7141761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (1.0 or 1.5 g orally)
Number of subjects: 16
Study 7141761 — intervention group
Group type: COMPARATOR
Intervention: Pindolol (1 mg i.v.)
Number of subjects: 16
Study 7141761 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (5 mg i.v.)
Number of subjects: 16
Study 30382499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PROP)
Number of subjects: 60
Study 30382499 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (SEVO)
Number of subjects: 60
Study 30382499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Propofol and Sevoflurane
Number of subjects: 60
Study 30144630 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH intervention (family-centered, community-based, individually-tailored behavioral intervention)
Number of subjects: 0
Study 30144630 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH intervention
Number of subjects: 0
Study 30144630 — intervention group
Group type: COMPARATOR
Intervention: Control arm (school readiness intervention delivered by the Nashville Public Library)
Number of subjects: 0
Study 27501160 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise intervention
Number of subjects: 136
Study 27501160 — intervention group
Group type: COMPARATOR
Intervention: Control group (provided environment and skills only)
Number of subjects: 136
Study 27501160 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intervention and control groups
Number of subjects: 136
Study 25075927 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk expression education and support intervention
Number of subjects: 40
Study 25075927 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 22370834 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization treatment
Number of subjects: 56
Study 22370834 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56
Study 19581812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (FibroScan)
Number of subjects: 45
Study 19581812 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRI
Number of subjects: 45
Study 19581812 — intervention group
Group type: EXPERIMENTAL
Intervention: Forns index
Number of subjects: 45
Study 19581812 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroScan
Number of subjects: 45
Study 19581812 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-spectroscopy
Number of subjects: 45
Study 19581812 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic steatosis
Number of subjects: 45
Study 18679605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihuang Zhixue Capsule (DZC), 2 to 3 capsules orally, thrice a day for 3 months
Number of subjects: 41
Study 18679605 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA), 3 mg/kg per day for 3 months
Number of subjects: 41
Study 18679605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 2 months treatment
Number of subjects: 41
Study 18679605 — intervention group
Group type: EXPERIMENTAL
Intervention: After 3 months treatment
Number of subjects: 41
Study 18679605 — intervention group
Group type: EXPERIMENTAL
Intervention: After 8 weeks treatment
Number of subjects: 41
Study 18679605 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 18679605 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 41
Study 16120823 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1590
Study 16120823 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1590
Study 16120823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1590
Study 16120823 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP lowering to 120 mmHg
Number of subjects: 1590
Study 16120823 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP below 120 mmHg
Number of subjects: 1590
Study 14506391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-S2/S HBV vaccine (GenHevac-B) 20 micro g, 3 intramuscular injections on days 0, 30, and 60
Number of subjects: 47
Study 14506391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 47
Study 11197317 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Self-Help (ASH)
Number of subjects: 1069
Study 11197317 — intervention group
Group type: COMPARATOR
Intervention: Manual Only (MAN)
Number of subjects: 1069
Study 9391135 — intervention group
Group type: EXPERIMENTAL
Intervention: cp‐52 (cold-passaged candidate vaccine virus)
Number of subjects: 0
Study 8459987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (32 mg i.v. single dose/day) plus dexamethasone (20 mg i.v. single dose/day)
Number of subjects: 113
Study 8459987 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (2 mg/kg or 1 mg/kg i.v. twice a day) plus dexamethasone (20 mg i.v. single dose/day)
Number of subjects: 113
Study 2428231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iloprost
Number of subjects: 24
Study 2428231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30422750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery garments (DPV576-C) worn overnight
Number of subjects: 38
Study 30422750 — intervention group
Group type: COMPARATOR
Intervention: Non-recovery garments (placebo) worn overnight
Number of subjects: 38
Study 29261568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic variables measured on day 1 in patients with early thrombocytopenia (group 1) and those who developed it later (group 2).
Number of subjects: 280
Study 29261568 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic variables measured on day 1 in patients without thrombocytopenia (group 3).
Number of subjects: 280
Study 29261568 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin activatable fibrinolysis inhibitor level and in vivo markers of fibrinolysis activation (plasmin‐antiplasmin complex, D‐dimer).
Number of subjects: 280
Study 29261568 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of impaired fibrinolysis and low platelets.
Number of subjects: 280
Study 27496855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 3950
Study 27496855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 3950
Study 27496855 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3950
Study 25203878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (bypass, sleeve or band)
Number of subjects: 57
Study 25203878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 57
Study 25203878 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical weight management (MWM)
Number of subjects: 57
Study 22782061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofill composite
Number of subjects: 41
Study 22782061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid composite
Number of subjects: 41
Study 22782061 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid composite
Number of subjects: 41
Study 20579218 — intervention group
Group type: EXPERIMENTAL
Intervention: immunochemical fecal occult blood test (iFOBT)
Number of subjects: 0
Study 20579218 — intervention group
Group type: COMPARATOR
Intervention: guaiac-based fecal occult blood test (gFOBT)
Number of subjects: 0
Study 17721254 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 0
Study 17721254 — intervention group
Group type: COMPARATOR
Intervention: Local/regional anesthesia techniques
Number of subjects: 0
Study 16085508 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site presentations of the study's background and aims
Number of subjects: 185
Study 16085508 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies for a 12-month randomized tobacco intervention trial
Number of subjects: 185
Study 12169503 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 91
Study 12169503 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 91
Study 10417499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 11
Study 10417499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg) plus Cimetidine (400 mg)
Number of subjects: 11
Study 10417499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7648219 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (specific classes not mentioned)
Number of subjects: 18
Study 2134115 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine (200-300 mg daily)
Number of subjects: 60
Study 2134115 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50-75 mg daily)
Number of subjects: 60
Study 7004723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (from 200 to 50 mmol/day)
Number of subjects: 21
Study 7004723 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of moderate salt restriction and high potassium intake (from 80 to 200 mmol/day)
Number of subjects: 21
Study 7004723 — intervention group
Group type: EXPERIMENTAL
Intervention: High potassium intake (from 80 to 200 mmol/day)
Number of subjects: 21
Study 7004723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 21
Study 7004723 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 21
Study 31509030 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct method (DM)
Number of subjects: 535
Study 31509030 — intervention group
Group type: COMPARATOR
Intervention: Standard method (SM)
Number of subjects: 535
Study 28555454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive training with aerobic exercises
Number of subjects: 32
Study 28555454 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercises (control group)
Number of subjects: 32
Study 25887744 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute physically active London 2012 Olympics-themed VFT
Number of subjects: 85
Study 25887744 — intervention group
Group type: COMPARATOR
Intervention: 30-minute sedentary version of the same VFT
Number of subjects: 85
Study 25887744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VFT
Number of subjects: 85
Study 23438248 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 91
Study 22231174 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin (SQH), 5,000 units subcutaneously three times daily
Number of subjects: 50
Study 22231174 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (IVH), titrated to an activated partial thromboplastin time of 40-45 s
Number of subjects: 50
Study 20237042 — intervention group
Group type: EXPERIMENTAL
Intervention: LDC 4% eye drops
Number of subjects: 24
Study 20237042 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PBO)
Number of subjects: 24
Study 17647293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine 30 mg daily for 24 weeks
Number of subjects: 86
Study 17647293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17102823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative craniospinal radiation therapy (36Gy+boost 20Gy to the posterior fossa)
Number of subjects: 48
Study 17102823 — intervention group
Group type: COMPARATOR
Intervention: Postoperative combination cranio-spinal radiation therapy (same dose as group I) and chemotherapy (vincristine, etoposide, cisplatin)
Number of subjects: 48
Study 17102823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative craniospinal radiation therapy (group I)
Number of subjects: 48
Study 17102823 — intervention group
Group type: COMPARATOR
Intervention: Postoperative combination cranio-spinal radiation therapy and chemotherapy (group II)
Number of subjects: 48
Study 12195129 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day (titrated to 100 mg/day)
Number of subjects: 82
Study 12195129 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg/day (titrated to 100 mg/day)
Number of subjects: 82
Study 12195129 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 82
Study 12195129 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 82
Study 12195129 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and Atenolol
Number of subjects: 82
Study 9457094 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging
Number of subjects: 60
Study 9457094 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional imaging
Number of subjects: 60
Study 7880189 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying interventions (specifics not provided)
Number of subjects: 0
Study 7880189 — intervention group
Group type: COMPARATOR
Intervention: Randomized, double-blind, placebo-controlled trials
Number of subjects: 0
Study 7880189 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses selected should be quantitative and standardized
Number of subjects: 0
Study 7880189 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate responses
Number of subjects: 0
Study 2198294 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5, and 0.75 mg)
Number of subjects: 7
Study 2198294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (100, 200, and 300 mg)
Number of subjects: 7
Study 2198294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2198294 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam and Pentobarbital
Number of subjects: 7
Study 2198294 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 7
Study 7182376 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar epidural analgesia for up to 24 hours
Number of subjects: 38
Study 7182376 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (thiopentone-oxygen-nitrous oxide-alcuronium-pethidine sequence with intermittent positive pressure ventilation)
Number of subjects: 38
Study 7182376 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 38
Study 7182376 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 38
Study 29987503 — intervention group
Group type: EXPERIMENTAL
Intervention: First Steps (FS) intervention
Number of subjects: 749
Study 29987503 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 749
Study 31311186 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention + 9 contextualized household visits (RANAS approach)
Number of subjects: 1500
Study 31311186 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention + 9 non-contextualized household visits
Number of subjects: 1500
Study 31311186 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention and 1 placebo household visit
Number of subjects: 1500
Study 28294080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sequential same-day tympanoplasty
Number of subjects: 38
Study 28294080 — intervention group
Group type: COMPARATOR
Intervention: Bilateral staged tympanoplasty performed 3 months apart
Number of subjects: 38
Study 25641761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME) and health education, 3 sessions over 1 month, followed by 2 months of home-based PFME.
Number of subjects: 54
Study 24220392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of high-molecular-weight hyaluronic acid (HA)
Number of subjects: 25
Study 24220392 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 25